Alexion Pharmaceuticals, Inc. is a multinational biopharmaceutical company based in Cheshire, Connecticut, USA.
The company is well known for being the the first developer and distributor of its sole marketed drug ‘Soliris’, which is the world’s first and only approved terminal complement inhibitor – used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Its flagship drug Soliris is currently approved in more than 50 countries as a treatment option for PNH. It is also approved as treatment for patients with atypical hemolytic uremic syndrome (aHUS) in the US, EU, and Japan.
Alexion was formed in 1992 and became a public company in 1996 on the NASDAQ stock exchange under the ticker symbol ‘ALXN’. It is now a multi-national company with more than 2,200 dedicated employees worldwide.
According to Alexion, the company is “focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases.”
Overview
- Chairman and CEO: Leonard Bell
- Industry: Pharmaceutical
- Type: Public company
- Listed on NASDAQ
- NASDAQ stock symbol: ALXN
- S&P 500 Component
- Founded: 1992
- Sales: $2.233 billion USD (2014)
- Net income: $656.912 million USD (2014)
- Earnings per share: $3.32 USD (2014)
- Company head office: 352 Knotter Drive Cheshire, CT 06410, USA
- Employees: 2,273 (2014)
- Website: http://www.alxn.com/
- Global headquarters contact number: 203-272-ALXN (2596)
Alexion Pharmaceuticals, Inc., Financial Results, Years Ended December 31
| Operating data (in $ thousands) | 2014 | 2013 |
| Net product sales | $2,233,733 | $1,551,346 |
| Total cost of sales | $173,862 | $177,556 |
| Research and development expenses | $513,782 | $317,093 |
| Selling, general, and administrative expenses | $630,209 | $489,720 |
| Acquisition-related costs | $20,295 | $5,029 |
| Total operating expenses | $1,191,165 | $845,780 |
| Operating income | $868,706 | $528,010 |
| Income before income taxes | $872,107 | $526,269 |
| Net income | $656,912 | $252,895 |
| Balance sheet data (in $ thousands) | ||
| Total assets | $4,201,962 | $3,317,696 |
| Total liabilities | $899,944 | $935,617 |
| Total stockholders’ equity | $3,302,018 | $2,382,079 |
| Common share data (in $) | ||
| Basic earnings per share | $3.32 | $1.29 |
| Diluted earnings per share | $3.26 | $1.27 |
Source: “Alexion Pharmaceuticals, Inc., Form 10-K 2014”